You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Details for Patent: 9,566,286


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 9,566,286 protect, and when does it expire?

Patent 9,566,286 protects ENSTILAR and is included in one NDA.

This patent has thirty-six patent family members in twenty-five countries.

Summary for Patent: 9,566,286
Title:Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Abstract: The present invention relates to a topical spray composition comprising a biologically active vitamin D derivative or analog and a corticosteroid, and its use in the treatment of dermal diseases and conditions.
Inventor(s): Lind; Marianne (Bagsv.ae butted.rd, DK), Rasmussen; Gritt (Virum, DK), Sonne; Mette Rydahl (Brondby Strand, DK), Hansen; Jens (Virum, DK), Petersson; Karsten (Ballerup, DK)
Assignee: LEO PHARMA A/S (Ballerup, DK)
Application Number:14/707,662
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,566,286
Patent Claim Types:
see list of patent claims
Composition; Compound; Device;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 9,566,286

Introduction

United States Patent 9,566,286, titled "Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid," is a patent that protects a specific formulation of a topical spray used in medical treatments. To analyze this patent, we need to delve into its claims, the patent landscape, and the implications of the 2024 USPTO guidance update on such inventions.

Patent Overview

The patent in question describes a pharmaceutical spray composition that includes a biologically active vitamin D derivative or analog and a corticosteroid. This composition is designed for topical application and is intended to treat various skin conditions.

Claims Analysis

Claim Structure

The claims section of a patent defines the scope of the invention. For US Patent 9,566,286, the claims would typically include:

  • Independent Claims: These define the broadest scope of the invention.
  • Dependent Claims: These narrow down the scope by adding additional limitations to the independent claims.

Subject Matter Eligibility

Under the 2024 USPTO guidance update, the subject matter eligibility of claims like those in US Patent 9,566,286 would be evaluated based on whether they integrate judicial exceptions into practical applications. For example, if a claim merely describes the use of a vitamin D analog and a corticosteroid without specifying a practical application, it might be considered ineligible. However, if the claim specifies how these components are used in a particular treatment or formulation that provides tangible benefits, it would likely be considered patent-eligible[1].

Claim Examples

  • Claim 1: A pharmaceutical spray composition comprising a biologically active vitamin D derivative and a corticosteroid. This claim is broad and might be considered ineligible if it does not specify a practical application.
  • Claim 2: The pharmaceutical spray composition of Claim 1, wherein the vitamin D derivative is calcipotriol and the corticosteroid is betamethasone, and the composition is used for treating psoriasis. This claim is more specific and integrates the judicial exception into a practical application, making it more likely to be patent-eligible[1].

Patent Landscape Analysis

Definition and Importance

Patent landscape analysis is a comprehensive approach to understanding the patent environment in a specific technology area. It helps in identifying key players, patent saturation, and areas of innovation[3].

Application to US Patent 9,566,286

For this patent, a patent landscape analysis would involve:

  • Identifying Competitors: Analyzing other patents and patent applications in the field of pharmaceutical spray compositions, particularly those involving vitamin D analogs and corticosteroids.
  • Technology Saturation: Determining the level of patent activity in this area to understand if it is a highly saturated field or if there are opportunities for further innovation.
  • Strategic Insights: Using the analysis to guide R&D and business decisions, such as whether to invest in this technology area or to pivot to newer inventive spaces[3].

Practical Applications and Benefits

Real-World Applications

The patent specifies a practical application of the pharmaceutical spray composition, such as treating psoriasis. This real-world application is crucial for demonstrating the patent eligibility of the claim. By showing how the composition improves the treatment of a specific condition, the patent can argue for its eligibility based on providing tangible benefits[1].

Tangible Benefits

The composition described in the patent offers several tangible benefits, including:

  • Improved Treatment Outcomes: The combination of a vitamin D analog and a corticosteroid can enhance the efficacy of psoriasis treatment.
  • Convenience: The spray formulation can be more convenient for patients compared to other forms of treatment.
  • Reduced Side Effects: The specific combination and formulation may reduce side effects associated with individual components when used separately[4].

Impact of 2024 USPTO Guidance Update

The 2024 USPTO guidance update emphasizes the importance of integrating judicial exceptions into practical applications. For patents like US 9,566,286, this means that the claims must clearly demonstrate how the invention provides concrete technological improvements and tangible benefits. The update also clarifies that the use of AI in developing the invention does not affect its subject matter eligibility, provided there is significant human contribution[1].

Key Takeaways

  • Claims Must Specify Practical Applications: To be patent-eligible, claims must integrate judicial exceptions into practical applications.
  • Patent Landscape Analysis is Crucial: This analysis helps in understanding the competitive landscape and making strategic decisions.
  • Tangible Benefits are Essential: The patent must demonstrate how the invention provides tangible benefits and improves technology.
  • Compliance with USPTO Guidance: Ensuring that the claims comply with the 2024 USPTO guidance update is vital for maintaining patent eligibility.

FAQs

Q: What is the main difference between Claim 1 and Claim 2 in a patent like US 9,566,286? A: Claim 1 is typically broader and might not specify a practical application, while Claim 2 is more specific and integrates the judicial exception into a practical application, making it more likely to be patent-eligible.

Q: How does the 2024 USPTO guidance update affect AI-assisted inventions? A: The update clarifies that the method of invention development, including the use of AI, does not impact subject matter eligibility, provided there is significant human contribution.

Q: What is the purpose of a patent landscape analysis? A: It helps in understanding the patent environment, identifying key players, and making strategic decisions about innovation and investment.

Q: Why is specifying a practical application important in patent claims? A: Specifying a practical application is crucial for demonstrating that the claim integrates judicial exceptions into a practical application, thereby meeting the criteria for patent eligibility.

Q: How many patent applications are filed each year in the United States? A: More than 300,000 U.S. utility patent applications are filed each year by people and companies from all over the world[2].

Cited Sources

  1. Understanding the 2024 USPTO Guidance Update on AI Patent - Mintz
  2. FAQ: Intellectual Property/Patents/Tech Transfer - University of Michigan
  3. Patent Landscape Analysis - Uncovering Strategic Insights - AcclaimIP
  4. Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid - Google Patents

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 9,566,286

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Leo Pharma As ENSTILAR betamethasone dipropionate; calcipotriene AEROSOL, FOAM;TOPICAL 207589-001 Oct 16, 2015 AB RX Yes Yes 9,566,286 ⤷  Subscribe Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,566,286

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2011264198 ⤷  Subscribe
Brazil 112012030653 ⤷  Subscribe
Canada 2800181 ⤷  Subscribe
China 102939078 ⤷  Subscribe
Cyprus 1115991 ⤷  Subscribe
Denmark 2579852 ⤷  Subscribe
European Patent Office 2579852 ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.